Scarica l'app Stockscreener
152.48
1.06%
1.60
Pre-mercato:
149.44
-3.04
-1.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$150.88
Aprire:
$151.13
Volume 24 ore:
853.45K
Relative Volume:
0.90
Capitalizzazione di mercato:
$15.20B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
51.69
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
+6.24%
1M Prestazione:
+6.47%
6M Prestazione:
+22.41%
1 anno Prestazione:
+21.12%
Intervallo 1D:
$150.84
$153.79
Intervallo di 1 settimana:
$146.00
$153.79
Portata 52W:
$84.23
$157.67
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
152.48 | 15.04B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
124.44 | 56.08B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 45.68B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.67 | 43.64B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
26.88 | 30.66B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.14 | 20.67B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityWeekly Volume Report & Weekly Breakout Opportunity Watchlist - Newser
Will Neurocrine Biosciences Inc. (NB3) stock gain from green policies2025 Investor Takeaways & Safe Entry Momentum Tips - Newser
Neurocrine Biosciences fails mid-stage study of depression drug - MSN
Neurocrine Biosciences Insider Sold Shares Worth $905,881, According to a Recent SEC Filing - MarketScreener
Will Neurocrine Biosciences Inc. (NB3) stock benefit from sector leadershipJuly 2025 Movers & Daily Risk Controlled Trade Plans - Newser
Why Neurocrine Biosciences Inc. (NB3) stock could rally strongly2025 Retail Activity & Accurate Buy Signal Notifications - Newser
Can Neurocrine Biosciences Inc. stock attract ESG capital inflowsWall Street Watch & Free Technical Confirmation Trade Alerts - Newser
Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZA’s Clinical Profile - simplywall.st
Why Neurocrine Biosciences Inc. (NB3) stock remains top rated2025 Short Interest & Fast Moving Trade Plans - Newser
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusQuarterly Profit Report & Growth Focused Entry Reports - Newser
Deutsche Bank Raises Price Target on Neurocrine Biosciences to $152 From $142, Keeps Hold Rating - MarketScreener
(NBIX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation Following New Narrative Review on VMAT2 Therapies - simplywall.st
Neurocrine Bio. stock jumps as rival drug faces modest Medicare price cut - Investing.com Canada
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication - Yahoo Finance
Published on: 2025-11-28 13:55:28 - BỘ NỘI VỤ
Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now - sharewise.com
Does Neurocrine Biosciences’ 9.8% Jump Signal a New Valuation Opportunity in 2025? - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Neurocrine Biosciences Insider Sold Shares Worth $2,150,513, According to a Recent SEC Filing - MarketScreener
Neurocrine Biosciences Director Sells 15,000 Shares - TradingView
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine Bio. stock rises as Stifel sees positive IRA impact from Austedo price cut - Investing.com Australia
Neurocrine Bio. stock rises as Stifel sees positive IRA impact from Austedo price cut By Investing.com - Investing.com South Africa
Gimme shelter: Neurocrine, Lilly spared in CMS price cut fallout - BioWorld MedTech
Neurocrine Extends Eiry W. Roberts’ Employment Term - The Globe and Mail
Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting - MSN
Neurocrine's collaboration for pipeline and market expansion - MarketScreener
[8-K] NEUROCRINE BIOSCIENCES INC Reports Material Event | NBIX SEC FilingForm 8-K - Stock Titan
Neurocrine Biosciences, Inc.Common Stock (NQ: NBIX - Markets Financial Content
Neurocrine review highlights key differences between tardive dyskinesia drugs - Indian Pharma Post
Distinctions Between VMAT2 Inhibitors Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Neurocrine publishes review highlighting differences between tardive dyskinesia treatments By Investing.com - Investing.com Canada
United States Congenital Adrenal Hyperplasia Treatment - openPR.com
Neurocrine Biosciences Inc Stock Analysis and ForecastEarnings Forecast Updates & High Yield Investment Portfolio - earlytimes.in
A Look at Neurocrine Biosciences (NBIX) Valuation After Setback in Depression Drug Trial - simplywall.st
What analysts say about Neurocrine Biosciences Inc stockMarket Depth Overview & Small Budget Big Profits - earlytimes.in
Asia Deal Watch: GSK To Collaborate With LTZ On Myeloid Cell Engagers - Citeline News & Insights
Is Neurocrine Biosciences Inc. (NB3) stock a safe buy pre earningsProfit Target & AI Based Trade Execution Alerts - newser.com
Neurocrine publishes review highlighting differences between tardive dyskinesia treatments - Investing.com
Neurocrine study highlights differences between tardive dyskinesia drugs - StreetInsider
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules - PR Newswire
How Neurocrine Biosciences Inc. stock reacts to bond yieldsFed Meeting & Weekly Momentum Picks - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy for dividend portfoliosWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com
What makes Neurocrine Biosciences Inc. (NB3) stock appealing to growth investorsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com
Can Neurocrine Biosciences Inc. stock weather global recessionJuly 2025 Short Interest & Smart Money Movement Alerts - newser.com
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.09%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):